Search Medical Condition
Please enter condition
Please choose location from dropdown

Troisdorf, Germany Clinical Trials

A listing of Troisdorf, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (261) clinical trials

Antipsychotic Induced Structural and Functional Brain Changes

Patients with diagnosis of schizophrenia according to DSM-5 admitted to a hospital participating in the consortium will undergo magnetic resonance imaging (MRI) as soon as possible after admission. Ideally, this procedure is performed before initiation of antipsychotic treatment (benzodiazepines are allowed). If not possible for clinical reasons, antipsychotic treatment will ...

Phase

5.64 miles

Learn More »

Praegnant Breast Cancer

Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis. Not only with regard to therapy decisions but also with regard to quality assured healthcare and health economics this entity of patients remains a challenge. Recently, novel advances in ...

Phase N/A

5.64 miles

Learn More »

Theory of Mind in Preschool Children School Children Youths and Adults Born Preterm or Full-term

Is there any difference in the development of theory of mind between preterms and full-terms? Is there a risk group of preterms to develop a deficit in theroy of mind? Four groups are tested: prescoolers (again two years later), youths and young adults. All participants were tested for theory of ...

Phase N/A

5.64 miles

Learn More »

Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer. The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease. Patients with recurrent, platinum-sensitive, ovarian, fallopian tube and peritoneal ...

Phase N/A

5.64 miles

Learn More »

Patient Preference for Pegfilgrastim (Neulasta ) Application Forms

Neutropenia is one of the most common side effects of myelosuppressive chemotherapy. Febrile neutropenia and infectious complications are associated with chemotherapy dose delays and reductions and an increased risk of hospitalization. Prophylaxis with recombinant G-CSFs reduces the incidence, severity and duration of CIN and the risk of developing FN. Pegfilgrastim ...

Phase N/A

5.64 miles

Learn More »

5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities

Patients will receive a second PD P 506 A-PDT on all AK lesions 1-2 weeks after the first PDT.

Phase

5.64 miles

Learn More »

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

This study will consist of 4 study periods of up to 50 months in total, consisting of: Screening Period - A maximum screening duration of 4 weeks. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months. End of Treatment Visit - A ...

Phase

5.88 miles

Learn More »

A Multicenter Study to Evaluate the Nutritional Suitability of Renastart

A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD) Primary Objective To investigate the nutritional suitability of ...

Phase N/A

5.88 miles

Learn More »

AMPLATZER Amulet LAA Occluder Trial

The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device (treatment) or a Boston Scientific WATCHMAN LAA closure ...

Phase N/A

5.88 miles

Learn More »

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

This is a prospective, open-label, multi-center, single arm, non-comparative phase II study in women with HR+/HER2- advanced breast cancer receiving palbociclib in addition to an aromatase inhibitor or fulvestrant. The study will take place in Germany (85 study centers). In total, 360 patients will be enrolled in this study. 6 ...

Phase

5.88 miles

Learn More »